Aldehyde dehydrogenase-2 is a host factor required for effective bone marrow mesenchymal stem cell therapy

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Ischemic Injury Research

Background:

• Mesenchymal stem cell (MSC) therapy shows promise for ischemic injuries but faces limitations due to unclear environmental regulatory mechanisms.
• Aldehyde dehydrogenase-2 (ALDH2) plays a crucial role in microenvironment homeostasis post-ischemia.
• A significant portion of the global population carries a loss-of-function ALDH2 allele, potentially impacting MSC therapy efficacy.

Purpose of the Study:

• To investigate whether host aldehyde dehydrogenase-2 (ALDH2) regulates the therapeutic potential of donor MSCs.
• To determine the mechanisms by which host ALDH2 influences MSC retention and efficacy in ischemic tissues.

Main Methods:

• Induction of limb ischemia in mice followed by intramuscular injection of MSCs.
• Assessment of MSC retention, blood perfusion, limb necrosis, and fibrosis at various time points post-transplantation.
• Analysis of the impact of ALDH2 deficiency and overexpression on MSC therapeutic effects.

Main Results:

• ALDH2-deficient host tissue significantly reduced MSC retention, perfusion recovery, and limb salvage compared to wild-type.
• Local ALDH2 overexpression enhanced the tissue microenvironment and magnified MSC-induced therapeutic improvements.
• Host ALDH2 mediated transplanted MSC survival and therapy by regulating capillary density, energy supply, and oxidative stress.

Conclusions:

• Aldehyde dehydrogenase-2 (ALDH2) is established as a key mediator of the host stem cell niche for optimizing MSC therapy.
• ALDH2 deficiency in the general population represents a significant limiting host factor for successful MSC therapy.